USD 3.22
(0.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 3.77 Million USD | -55.72% |
2022 | 8.51 Million USD | 632.52% |
2021 | 1.16 Million USD | -13.58% |
2020 | 1.34 Million USD | 59.25% |
2019 | 844.98 Thousand USD | 70.59% |
2018 | 495.33 Thousand USD | -0.92% |
2017 | 499.94 Thousand USD | -17.72% |
2016 | 607.61 Thousand USD | -58.76% |
2015 | 1.47 Million USD | -29.39% |
2014 | 2.08 Million USD | 52.88% |
2013 | 1.36 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 6.99 Million USD | 85.38% |
2024 Q2 | 1.54 Million USD | -77.85% |
2023 Q4 | 3.77 Million USD | -27.12% |
2023 Q2 | 6.23 Million USD | 4.98% |
2023 FY | 3.77 Million USD | -55.72% |
2023 Q3 | 5.17 Million USD | -16.96% |
2023 Q1 | 5.93 Million USD | -30.3% |
2022 Q2 | 1.69 Million USD | -7.29% |
2022 Q1 | 1.82 Million USD | 57.06% |
2022 FY | 8.51 Million USD | 632.52% |
2022 Q4 | 8.51 Million USD | 391.46% |
2022 Q3 | 1.73 Million USD | 2.36% |
2021 Q2 | 1.99 Million USD | 64.29% |
2021 Q3 | 1.97 Million USD | -1.07% |
2021 Q4 | 1.16 Million USD | -40.98% |
2021 Q1 | 1.21 Million USD | -9.92% |
2021 FY | 1.16 Million USD | -13.58% |
2020 Q2 | 1.33 Million USD | -13.3% |
2020 Q3 | 1.47 Million USD | 9.92% |
2020 Q4 | 1.34 Million USD | -8.53% |
2020 Q1 | 1.54 Million USD | 82.68% |
2020 FY | 1.34 Million USD | 59.25% |
2019 Q3 | 906.21 Thousand USD | -10.28% |
2019 FY | 844.98 Thousand USD | 70.59% |
2019 Q4 | 844.98 Thousand USD | -6.76% |
2019 Q2 | 1.01 Million USD | -51.5% |
2019 Q1 | 2.08 Million USD | 320.48% |
2018 Q3 | 398.57 Thousand USD | -32.05% |
2018 Q4 | 495.33 Thousand USD | 24.28% |
2018 FY | 495.33 Thousand USD | -0.92% |
2018 Q1 | 600 Thousand USD | 20.01% |
2018 Q2 | 586.52 Thousand USD | -2.25% |
2017 Q2 | 769.01 Thousand USD | -3.54% |
2017 Q1 | 797.26 Thousand USD | 31.21% |
2017 FY | 499.94 Thousand USD | -17.72% |
2017 Q4 | 499.94 Thousand USD | -33.91% |
2017 Q3 | 756.49 Thousand USD | -1.63% |
2016 Q1 | - USD | -100.0% |
2016 FY | 607.61 Thousand USD | -58.76% |
2016 Q4 | 607.61 Thousand USD | -70.9% |
2016 Q3 | 2.08 Million USD | 5.22% |
2016 Q2 | 1.98 Million USD | 0.0% |
2015 Q1 | - USD | -100.0% |
2015 Q4 | 1.47 Million USD | 33.5% |
2015 Q3 | 1.1 Million USD | 0.0% |
2015 FY | 1.47 Million USD | -29.39% |
2014 FY | 2.08 Million USD | 52.88% |
2014 Q4 | 2.08 Million USD | 0.0% |
2013 FY | 1.36 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Collegium Pharmaceutical, Inc. | 947.87 Million USD | 99.602% |
Embecta Corp. | 2.03 Billion USD | 99.815% |
ANI Pharmaceuticals, Inc. | 471.67 Million USD | 99.2% |
Dynavax Technologies Corporation | 375.02 Million USD | 98.994% |
Esperion Therapeutics, Inc. | 660.79 Million USD | 99.429% |
Pacira BioSciences, Inc. | 704.25 Million USD | 99.464% |
PainReform Ltd. | 2.69 Million USD | -40.176% |
Aquestive Therapeutics, Inc. | 163.9 Million USD | 97.699% |
Sunshine Biopharma, Inc. | 6.13 Million USD | 38.561% |
SCYNEXIS, Inc. | 55.45 Million USD | 93.197% |
China SXT Pharmaceuticals, Inc. | 9.19 Million USD | 58.983% |
Cosmos Health Inc. | 30.25 Million USD | 87.531% |
Journey Medical Corporation | 56.49 Million USD | 93.324% |
Sunshine Biopharma, Inc. | 6.13 Million USD | 38.561% |
Safety Shot Inc | 3.89 Million USD | 3.081% |
Alpha Teknova, Inc. | 38.55 Million USD | 90.215% |
Intra-Cellular Therapies, Inc. | 136.87 Million USD | 97.244% |
Bright Green Corporation | 6.43 Million USD | 41.409% |
Procaps Group, S.A. | 462.06 Million USD | 99.184% |
Theratechnologies Inc. | 98.63 Million USD | 96.176% |
Harrow Health, Inc. | 241.75 Million USD | 98.44% |
Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | 56.919% |
Biofrontera Inc. | 23.13 Million USD | 83.698% |
DURECT Corporation | 30.4 Million USD | 87.594% |
Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 99.226% |
Cronos Group Inc. | 43.73 Million USD | 91.375% |
OptiNose, Inc. | 194.33 Million USD | 98.059% |
Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 99.539% |
Kala Pharmaceuticals, Inc. | 48.44 Million USD | 92.214% |
RedHill Biopharma Ltd. | 20.97 Million USD | 82.019% |
Organogenesis Holdings Inc. | 181.36 Million USD | 97.92% |
Cumberland Pharmaceuticals Inc. | 52.51 Million USD | 92.817% |
Radius Health, Inc. | 804.29 Million USD | 99.531% |
Universe Pharmaceuticals INC | 13.75 Million USD | 72.575% |
ProPhase Labs, Inc. | 42.54 Million USD | 91.134% |
Phibro Animal Health Corporation | 725.54 Million USD | 99.48% |
Procaps Group S.A. | 462.06 Million USD | 99.184% |
Alvotech | 1.88 Billion USD | 99.8% |
TherapeuticsMD, Inc. | 14.02 Million USD | 73.098% |
Viatris Inc. | 27.21 Billion USD | 99.986% |
Rockwell Medical, Inc. | 30.88 Million USD | 87.785% |
Aytu BioPharma, Inc. | 90.37 Million USD | 95.826% |
SIGA Technologies, Inc. | 57.97 Million USD | 93.494% |
Tilray Brands, Inc. | 892.11 Million USD | 99.577% |
Lifecore Biomedical, Inc. | 219.8 Million USD | 98.284% |
Shineco, Inc. | 47.6 Million USD | 92.076% |
PetIQ, Inc. | 645.22 Million USD | 99.415% |
Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -1618.418% |
Incannex Healthcare Limited | 5.83 Million USD | 35.298% |
Neurocrine Biosciences, Inc. | 1.01 Billion USD | 99.63% |
Alimera Sciences, Inc. | 107.35 Million USD | 96.486% |
Silver Spike Investment Corp. | 3 Million USD | -25.327% |
Assertio Holdings, Inc. | 148.41 Million USD | 97.458% |
Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -98.956% |
Petros Pharmaceuticals, Inc. | 21.31 Million USD | 82.304% |
Clever Leaves Holdings Inc. | 7.02 Million USD | 46.312% |
Cyclo Therapeutics, Inc. | 8.49 Million USD | 55.572% |
Avadel Pharmaceuticals plc | 173.38 Million USD | 97.824% |
Hempacco Co., Inc. | 18.82 Million USD | 79.959% |
Talphera, Inc. | 6.29 Million USD | 40.03% |
Alvotech | 1.88 Billion USD | 99.8% |
Eagle Pharmaceuticals, Inc. | 172.6 Million USD | 97.815% |
Lantheus Holdings, Inc. | 835.25 Million USD | 99.548% |
Currenc Group, Inc. | 177.67 Million USD | 97.877% |
Kamada Ltd. | 109.96 Million USD | 96.57% |
Indivior PLC | 1.95 Billion USD | 99.807% |
Evoke Pharma, Inc. | 9.64 Million USD | 60.903% |
Flora Growth Corp. | 17.22 Million USD | 78.097% |
Cyclo Therapeutics, Inc. | 8.49 Million USD | 55.572% |
Evolus, Inc. | 209.68 Million USD | 98.201% |
HUTCHMED (China) Limited | 536.38 Million USD | 99.297% |
Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 99.568% |
Akanda Corp. | 12.66 Million USD | 70.225% |